2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 927

2015 ACR/ARHP Workforce Study in the United States: Pediatric Rheumatologist Supply and Demand Projections for 2015-2030
Abstract Number: 928

2015 ACR/ARHP Workforce Study in the United States: A Maldistribution of Adult Rheumatologists
Abstract Number: 929

Retinal Examinations Among SLE Patients Newly-Initiating Hydroxychloroquine in a U.S. Medicaid SLE Population, 2000-10
Abstract Number: 930

How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project
Abstract Number: 931

Rates of Lipid Testing and Statin Prescriptions Among SLE and Diabetes Mellitus Patients in a Nationwide Medicaid Cohort
Abstract Number: 932

High Symptom Prevalence and Under-Utilisation of Palliative Care at End-of-Life of Patients with Systemic Rheumatic Diseases
Abstract Number: 933

Erosion Patterns in Seropositive and Seronegative Rheumatoid Arthritis: A Joint-By-Joint Approach
Abstract Number: 934

Magnetic Resonance Imaging (MRI) Joint Space Narrowing Is an Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis
Abstract Number: 935

Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis
Abstract Number: 936

Reliability and Responsiveness of an Omeract Tenosynovitis Magnetic Resonance Imaging Scoring System for the Rheumatoid Arthritis Wrist and Hand
Abstract Number: 937

Distal Interphalangeal Joint Erosions Assessed By HR-pQCT in Patients with Psoriatic Onycholysis
Abstract Number: 938

Prevalence of Non-Radiographic Axial Spondyloarthritis in Psoriatic Arthritis – a Single Center Observational Study
Abstract Number: 939

Circulating IgG4 Antibody Secreting Cells Are Better Biomarker of Disease Activity Compared to Serum IgG4 Levels in Patients with IgG4-Related Disease
Abstract Number: 940

A Trial of XmAb®5871, a Reversible Inhibitor of CD19+ Cells, in IgG4-Related Disease
Abstract Number: 941

An International, Multi-Specialty Validation Study of the IgG4-Related Disease Responder Index

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].